PHI with Peritoneal carcinomatosis
How does this condition affect your private health insurance?
Peritoneal carcinomatosis (Peritonealkarzinose) is a condition where cancer cells have spread to the peritoneum, the membrane lining the abdominal cavity and covering the abdominal organs. It typically arises as a metastatic complication from primary cancers like ovarian, colorectal, gastric, or pancreatic cancer. This advanced stage often signifies widespread disease, leading to symptoms such as abdominal pain, distension, ascites (fluid accumulation), nausea, and bowel obstruction. Diagnosis usually involves imaging (CT, MRI), laparoscopy, and biopsy. Treatment is complex, often involving cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), systemic chemotherapy, or palliative care, aiming to improve quality of life and potentially extend survival, though prognosis remains challenging.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for symptom progression leading to diagnosis.
Duration of Illness (Lifetime)
Chronic and progressive, typically until death.
Cost of Treatment (Initial)
Very high (e.g., hundreds of thousands of dollars for CRS/HIPEC and prolonged hospital stays).
Cost of Treatment (Lifetime)
Very high, often extending into hundreds of thousands to millions of dollars due to ongoing systemic therapies, surgeries, and palliative care.
Mortality Rate
High (often >80-90% within 5 years, depending on primary cancer and treatment response).
Risk of Secondary Damages
Very high (e.g., bowel obstruction, ascites, malnutrition, severe pain, psychological distress, organ dysfunction).
Probability of Full Recovery
Low (typically <10%, often involving careful selection of patients for aggressive treatments like CRS/HIPEC, but recurrence is common).
Underlying Disease Risk
100% (always secondary to a primary cancer such as ovarian, colorectal, gastric, or pancreatic cancer).